Ideaya Biosciences opened lower at $32.07, compared with its previous close of $32.72. In the last trading session, the stock traded between $31.45 and $32.51. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Ideaya Biosciences is now worth
$ 139.50
Giving a profit of
$ 39.50 (39.50%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.24 (-3.80%)
Day High
$32.51
Day Low
$31.45
Day Open
$32.07
Prev Close
$32.72
Volume
4,42,019
1W Return
-2.89%
1M Return
-12.69%
3M Return
-14.62%
6M Return
11.88%
1Y Return
-1.68%
Fundamentals
Market Cap ($ Mn)
3,043
PE Ratio
-
PB Ratio
3.22
PEG Ratio
-
ROE
-11.02%
ROCE
-15.07%
EPS (TTM)
$-1.30
Investment Returns
1 Week
-2.89%
1 Month
-12.69%
3 Months
-14.62%
6 Months
11.88%
9 Months
-1.34%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
207.8
Sep 25
10.9
Dec 25
8.9
Jun 26
10.2
Sep 26
Updates
10Nov
Mizuho lowers IDEAYA Biosciences price target to $39, keeps outperform
Mizuho lowered IDEAYA Biosciences price target from $44 to $39. Analyst Graig Suvannavejh maintained an Outperform rating. The revision reflects a $5 reduction in the projected share value.
2 days ago
6Nov
Citigroup raises IDEAYA Biosciences price target to $66, keeps Buy
Citigroup raises IDEAYA Biosciences price target to $66. Analyst Yigal Nochomovitz maintains Buy rating. Target increased from previous level of $65.
7 days ago
5Nov
Truist Securities reiterates Buy on IDEAYA, lowers target to $57
Truist Securities reiterated a Buy rating on IDEAYA Biosciences. Price target lowered from $59 to $57 by analyst Gregory Renza. No change in investment stance despite reduced valuation.
8 days ago
5Nov
RBC lowers IDEAYA Biosciences price target to $45, maintains Outperform
RBC Capital analyst Leonid Timashev lowered the price target for IDEAYA Biosciences. The new price target is set at $45, down from the previous $48. The firm maintained an Outperform rating on the stock.
8 days ago
3Nov
IDEAYA Biosciences Q3 Results: Loss widens to $(1.22) despite sales beat
IDEAYA Biosciences reported a Q3 loss of $(1.22) per share, missing the $(1.18) estimate by 4.27%. Quarterly sales of $10.242 million beat the $6.857 million consensus estimate by 49.36%. Revenue declined 95.07% YoY from $207.834 million in the prior year period. Earnings per share decreased 191.73% YoY from a positive $1.33 in the same period last year.
9 days ago
16Oct
William Blair initiates IDEAYA Biosciences with Outperform rating
William Blair initiates coverage on IDEAYA Biosciences. Analyst Alethia Young assigns an Outperform rating. No price target or financial data disclosed in the notice.
